Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,122 total articles
Steven L. Cook, Chief Financial Officer of Omada Health, Inc. (NASDAQ:OMDA), recently completed a series of share sales totaling $1,034,616 between June 26 and June 29, 2026. The transactions, executed under a 10b5-1 trading plan established in March 2026, spanned a price range of $19.6727 to $21.0678 per share. Following these sales, Cook retains …
Jason P. Rhodes, a director at Dyne Therapeutics, Inc. (NASDAQ:DYN), recently completed the sale of 504,695 shares of the company's common stock, generating approximately $10.7 million in proceeds. The transactions occurred on June 26 and June 29, 2026, with shares sold at prices ranging from $21.14 to $21.28. These sales were executed under a Rule…
Micron Technology Inc. (NASDAQ: MU) President and Chief Executive Officer Sanjay Mehrotra executed a significant stock sale on June 26, 2026, divesting 26,736 shares for a total value of $32,761,315. The transactions, priced between $1,128.41 and $1,169.96 per share, were conducted under a Rule 10b5-1 trading plan established earlier in the year. T…
Micron Technology Inc. (NASDAQ: MU) President and CEO Sanjay Mehrotra sold 11,294 shares of the company's common stock on June 26, 2026, realizing proceeds of $13,573,976. The transactions were executed at prices between $1,170.60 and $1,192.42 per share under a Rule 10b5-1 trading plan established earlier in the year. Following the sale, Mehrotra …
Samira Shaikhly, Septerna’s Chief People Officer, executed a transaction involving the exercise of stock options and the subsequent sale of 2,178 shares, netting $76,622. The move, structured under a Rule 10b5-1 plan adopted in late 2025, occurs against a backdrop of significant stock appreciation and ongoing clinical developments for the company’s…
Jon Congleton, Chief Executive Officer of Mineralys Therapeutics, Inc. (NASDAQ: MLYS), has completed a series of stock transactions totaling approximately $1.96 million. The sales were executed under a Rule 10b5-1 trading plan established in late December 2025. This executive activity occurs against the backdrop of the company's ongoing financial r…
Eric Warren, Chief Commercial Officer at Mineralys Therapeutics, Inc. (NASDAQ: MLYS), recently completed the sale of 104,124 shares of the company's common stock. The transaction, valued at approximately $2,696,322, was carried out on June 26, 2026. This sale was executed under the framework of a pre-arranged Rule 10b5-1 trading plan, which Mr. War…
Susan M. Byrne, serving as Director Emerita at Westwood Holdings Group Inc. (NASDAQ: WHG), has executed a series of stock sales totaling approximately $246,550 during late June. The transactions were carried out under a Rule 10b5-1 trading plan established on April 1, 2026. Following these dispositions, Byrne retains a direct stake of 239,017 share…
Joshua Hug, a director at Remitly Global, Inc. (NASDAQ:RELY), completed a total sale of $764,400 in company shares over two days in late June. The transactions were executed automatically under a Rule 10b5-1 trading plan established in December 2025. This divestment occurs as Remitly's stock price has risen significantly, trading around $22.42, whi…
Kelly Bliss, president of the U.S. Group Health division at Teladoc Health, Inc. (NASDAQ:TDOC), has executed a sale of 2,500 shares of the company's common stock. The transaction, which netted $21,250, was conducted under a Rule 10b5-1 trading plan established in August 2025. This sale takes place as Teladoc Health navigates a period of strategic e…
Rahul Khara, Chief Legal Officer at Disc Medicine, Inc. (NASDAQ:IRON), sold 2,500 shares of common stock for $187,500 in late June 2026. The sales occurred on June 26 and June 29, 2026, at $75.00 per share. These sales followed the acquisition of an equal number of shares through the exercise of stock options at $14.69 per share, totaling $36,725. …
Joseph Baroldi, Executive Vice President and Chief Business Officer at Ionis Pharmaceuticals Inc. (NASDAQ: IONS), disclosed that his spouse executed a series of transactions involving the company’s common stock on June 26, 2026. The spouse sold 5,635 shares through a pre-arranged Rule 10b5-1 trading plan, generating $451,698, while simultaneously a…
Patrick R. O’Neil, Executive Vice President, Chief Legal Officer, and General Counsel at Ionis Pharmaceuticals (NASDAQ: IONS), executed a sale of company stock on June 26, 2026. The transaction, valued at $245,520, involved the disposal of 3,069 shares at a price of $80.00 per share. The sale was conducted pursuant to a Rule 10b5-1 trading plan est…
Eugene Schneider, Executive Vice President and Chief Clinical Development Officer at Ionis Pharmaceuticals Inc. (NASDAQ:IONS), executed a series of transactions on June 26, 2026, involving the sale and acquisition of company stock. The sale, conducted under a Rule 10b5-1 trading plan, resulted in the disposal of 26,000 shares at a weighted average …
Jonathan Yen-Wen Yu, Chief Operating Officer of Disc Medicine, Inc. (NASDAQ:IRON), recently executed a series of stock transactions amounting to $21,750 in sales. The moves were carried out under a Rule 10b5-1 trading plan adopted in March 2026, following a concurrent acquisition of shares at a significantly lower price point. This activity occurs …
Guardant Health, Inc. (NASDAQ:GH) Chief Information Officer Kumud Kalia has executed a series of stock transactions involving the company’s common equity. The filings detail both sales and purchases of shares at prices hovering around the $130 mark. These personal trading activities occur against a backdrop of significant regulatory developments an…
Kymera Therapeutics, Inc. (NASDAQ:KYMR) director Bruce Booth facilitated the sale of approximately $3.42 million worth of common stock on June 29, 2026. The transaction involved 31,283 shares executed through two Atlas Venture funds under a Rule 10b5-1 trading plan. The sale occurs as KYMR shares have appreciated significantly over the past year, c…
Jesus Llorca, Executive Vice President and Chief Financial Officer of SEACOR Marine Holdings Inc. (NASDAQ:SMHI), executed the sale of 16,110 shares of company common stock through an automated Rule 10b5-1 trading plan. The transactions, which occurred on June 29 and June 30, 2026, yielded proceeds of $129,346. This executive divestment takes place …
Kymera Therapeutics director Bruce Booth has sold 500,000 shares of the company's common stock, totaling approximately $56.5 million. The transactions, executed through a Rule 10b5-1 trading plan adopted in late 2025, occurred on June 26 and June 29, 2026. This insider activity coincides with significant clinical progress for Kymera Therapeutics, s…
Adam Eltoukhy, serving as Executive Vice President, Chief Administrative Officer, and Secretary at Samsara Inc. (NASDAQ:IOT), completed a stock transaction valued at $65,411 on June 29, 2026. The sale involved 2,039 shares of Class A Common Stock executed at $32.08 per share. This divestment was facilitated through a Rule 10b5-1 trading plan, which…
CareDx Inc. (NASDAQ: CDNA) President and CEO John Walter Hanna Jr. executed a series of stock transactions in late June 2026, selling 40,000 shares valued at approximately $1.17 million. The sales were conducted under a Rule 10b5-1 trading plan established in December 2025. Concurrently, Hanna acquired 60,000 shares through the exercise of employee…
Andrew H. Everett II, Senior Vice President, General Counsel & Secretary of SEACOR Marine Holdings Inc. (NASDAQ: SMHI), sold 10,565 shares of the company’s common stock on June 29, 2026, for a total of $84,942. The transaction, executed under a Rule 10b5-1 plan adopted March 9, 2026, leaves Mr. Everett with 273,595 directly held shares. The sale oc…
Saba Capital Management, L.P., a significant shareholder in BlackRock ESG Capital Allocation Term Trust (NASDAQ:ECAT), executed a series of sales totaling approximately $2.91 million in late June. The transactions, which brought the firm's indirect ownership down to 17,742,619 shares, highlight active portfolio management within the trust. The trus…
Topline Capital Management, LLC and its managing member, Collin McBirney, executed a series of transactions resulting in the sale of NerdWallet, Inc. (NASDAQ: NRDS) common stock valued at approximately $17,862,921. The liquidation occurred across multiple days in late June 2026, with share prices fluctuating between $8.95 and $9.27. The shares were…
Halozyme Therapeutics director Mahesh Krishnan executed a $547,800 sale of common stock in late June 2026, following the exercise of stock options. The transaction occurred as the company's shares traded near their 52-week high, reflecting a strong 48% annual return. Concurrently, Halozyme announced leadership updates and confirmed minimal long-ter…
